China Medical System Holdings Limited announced on Feb, 12 2026 that it has entered into a ten-year exclusive distribution agreement with Teikoku Pharma USA, Inc. for Lidoderm 5% lidocaine cataplasms in mainland China, excluding Hong Kong, Macau and Taiwan.

Teikoku Pharma USA will be responsible for manufacturing and supply, while China Medical System will hold sole distribution rights. The agreement can be renewed after the initial term in accordance with its provisions.

Lidoderm, first approved by the U.S. FDA in 1999 for treating postherpetic neuralgia and cleared for sale in China in 2024, has shown in clinical studies that about 25% to 33% of patients achieved at least a 50% reduction in pain within four to 12 weeks.

The company said the product will broaden its pain-management portfolio and support expansion into both in-hospital and out-of-hospital sales channels.